CD4 and pulmonary fibrosis: Counterintuitive findings from another study showed that exogenous administration of the AHR ligand FICZ ameliorated pulmonary fibrosis, presumably by augmenting numbers of FoxP3+ Tregs and decreasing IFN-γ+ CD4+ and IL-17A+ γδ+ T cells (73).